Literature DB >> 29885924

Clinical Course of a Patient With Kidney Failure Due to Isolated Bilateral Renal Extramedullary Plasmacytomas.

Braden J Lawrence1, Emily L Petersen2, Wayne G Riches3, David C Pfeiffer4.   

Abstract

Plasmacytomas are rare immunoproliferative monoclonal plasma cell diseases of lymphoid lineage that may present in an isolated or systemic manner. Systemic involvement is much more common than occurrences isolated to a particular organ, and for this reason, it is imperative to rule out systemic involvement for osseous and nonosseous isolated neoplasms. These neoplasms present unique challenges due to their location, extent of involvement, vague presentation, and dearth of treatment protocol. We report the case of a 69-year-old man who developed chronic kidney disease stage 4 between 2009 and 2012. Precipitous kidney failure, anorexia, fatigue, and flank pain necessitated clinical follow-up that ultimately led to thorough imaging and bilateral kidney biopsy. Protein electrophoresis, immunohistochemistry, and immunofluorescence were all consistent with bilateral renal extramedullary plasmacytomas. Treatment recommendations are often limited to prior case successes; however, chemotherapy, radiation, and surgery are the mainstay of treatment. Although surgery or combined therapy provides the best results for patients, such options are unfeasible with bilateral kidney involvement. Therefore, a chemotherapy regimen, similar to that for multiple myeloma, was determined to be most reasonable. Treatment consisted of 4 cycles of a bortezomib, cyclophosphamide, and dexamethasone regimen. Three months following chemotherapy, kidney function returned to baseline levels.
Copyright © 2018 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extramedullary plasmacytoma (EMP); bilateral renal plasmacytomas (BREMPs); case report; chemotherapy; estimated glomerular filtration rate (eGFR); kidney biopsy; kidney failure; monoclonal gammopathy; neoplasm; plasma cell dyscrasias; renal EMP; renal tumor

Mesh:

Substances:

Year:  2018        PMID: 29885924     DOI: 10.1053/j.ajkd.2018.03.029

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  2 in total

1.  Renal extramedullary plasmacytoma in a dog.

Authors:  Jason Johnson; Germaine Hung; Victoria Larson; Jorden Manasse; Tim Spotswood
Journal:  Can Vet J       Date:  2021-10       Impact factor: 1.008

2.  Refractory primary extramedullary plasmacytoma in kidney: a case report.

Authors:  Wenjie Niu; Lili Zhang; Yuhai Wu; Kai Li; Lixia Sun; Hong Ji; Bing Zhang
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.